ArticleJournal of cancer research and clinical oncology2025
Dosimetry evaluation and uncertainty analysis of Cobalt-60 HDR brachytherapy for cervical cancer in resource-limited settings.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative. This study aims to evaluate the dosimetric performance and planning uncertainties associated with Co-60 HDR brachytherapy.
methodsA retrospective dosimetric analysis was conducted on 30 patients with FIGO stage IIB-IIIB cervical cancer, eligable for Brachytherapy, were treated using CT-guided intracavitary HDR brachytherapy with Co-60 sources. Treatment plans were assessed for high-risk clinical target volume (HR-CTV) coverage (D90, D80), dose-volume histogram parameters, and organ-at-risk (OAR) doses (D2cc for bladder, rectum, and sigmoid). Plan quality indices including conformity index (COIN), dose homogeneity index (DHI), and dose non-uniformity ratio (DNR) were calculated. Uncertainty analyses accounted for treatment planning system (TPS) variability and applicator positioning.
resultsThe mean HR-CTV D90 was 6.97 Gy, achieving 99.6% of the prescription dose. The mean D2cc values were 5.73 Gy for bladder (81.9%Rx), 4.72 Gy for rectum (67.4%Rx), and 3.23 Gy for sigmoid, all within acceptable tolerance limits. The mean COIN was 0.292, DHI 0.31, and DNR 0.69, indicating moderate dose conformity and acceptable inhomogeneity. TPS and applicator uncertainties contributed to estimated dose deviations of ± 2% and ± 1 mm, respectively.
conclusionCobalt-60 HDR brachytherapy provides clinically acceptable dose coverage and OAR sparing, with dosimetric outcomes comparable to Ir-192. Its longer half-life offers practical advantages for LMICs. Optimization of dose distribution and further validation through Monte Carlo simulations and prospective clinical studies are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.